288 related articles for article (PubMed ID: 18432176)
1. Antiplatelet therapy following drug-eluting stent implantation: new clinical data and recommendations.
Paradis JM; Ducrocq G; Tanguay JF
Minerva Cardioangiol; 2008 Feb; 56(1):139-54. PubMed ID: 18432176
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.
Ducrocq G; Serebruany V; Tanguay JF
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):939-53. PubMed ID: 17867923
[TBL] [Abstract][Full Text] [Related]
3. Stent thrombosis in the era of drug eluting stents.
Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA
Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038
[TBL] [Abstract][Full Text] [Related]
4. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?
Kumbhani DJ; Bavry AA; Bhatt DL
Indian Heart J; 2007; 59(2 Suppl B):B113-7. PubMed ID: 19153427
[TBL] [Abstract][Full Text] [Related]
5. Drug-eluting stent thrombosis.
Steinberg DH; Satler LF
Minerva Cardioangiol; 2008 Feb; 56(1):127-37. PubMed ID: 18432175
[TBL] [Abstract][Full Text] [Related]
6. [Optimal platelet inhibition after coronary stent implantation. Current status].
Silber S; Hoffmeister HM; Bode C
Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
8. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives.
Jaffe R; Strauss BH
J Am Coll Cardiol; 2007 Jul; 50(2):119-27. PubMed ID: 17616295
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Spinler SA
Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
[TBL] [Abstract][Full Text] [Related]
10. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study.
Burzotta F; Parma A; Pristipino C; Manzoli A; Belloni F; Sardella G; Rigattieri S; Danesi A; Mazzarotto P; Summaria F; Romagnoli E; Prati F; Trani C; Crea F
Eur Heart J; 2008 Dec; 29(24):3011-21. PubMed ID: 18987096
[TBL] [Abstract][Full Text] [Related]
11. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
12. Stent thrombosis.
Gupta S; Gupta MM
J Assoc Physicians India; 2008 Dec; 56():969-79. PubMed ID: 19322976
[TBL] [Abstract][Full Text] [Related]
13. [Stent thrombosis in the era of drug-eluting stents].
Wöhrle J
Herz; 2007 Aug; 32(5):411-8. PubMed ID: 17687531
[TBL] [Abstract][Full Text] [Related]
14. Drug-eluting coronary stents: many meta-analyses, little benefit.
Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
[TBL] [Abstract][Full Text] [Related]
15. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model.
Garg P; Cohen DJ; Gaziano T; Mauri L
J Am Coll Cardiol; 2008 May; 51(19):1844-53. PubMed ID: 18466798
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: findings from the GHOST Study (Guthrie Health System Off-Label StenT Study).
Harjai KJ; Orshaw P; Shenoy C; Acharji S; Sporn D; Aboufares A; Stapleton D
J Interv Cardiol; 2008 Aug; 21(4):315-24. PubMed ID: 18754967
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Rossini R; Musumeci G; Aprile A; Valsecchi O
Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):49-61. PubMed ID: 20121564
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
19. Drug-eluting stent thrombosis.
Stähli BE; Camici GG; Tanner FC
Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):45-52. PubMed ID: 19124388
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive balloon postdilatation after stent deployment: is it still necessary with drug-eluting stents?
Brodie BR
J Interv Cardiol; 2006 Feb; 19(1):43-50. PubMed ID: 16483339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
